Overview

Switching Undetectables to Selzentry

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

This pilot single arm, single site, open-labeled switch study seeks to enroll thirty (30) HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] and switch them to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs.

Phase:

Phase 4

Details

Lead Sponsor:

St. Hope Foundation

Collaborator:

GlaxoSmithKline

Treatments:

Integrase Inhibitors
Maraviroc
Protease Inhibitors
Reverse Transcriptase Inhibitors